| Revenue growth | +17.3% YoY; domestic ex-CH +15.9% |
|---|---|
| Margins | EBITDA margin 27.1%, +210 bps YoY; PAT margin 16.5% |
| Demand visibility | Secondary sales +15.7% vs IPM 14.2%; 1.1x outperformance |
Growth
Revenue +17.3% YoY; EBITDA +27.2%; PAT +37.7%. H1 FY27 revenue ₹8,368 Cr (+15.1%), PAT ₹1,290 Cr (+33.7%).
Outlook
No numeric FY27 guidance stated. H1 FY27 capex ₹412 Cr (4.9% of revenue); Armed Cell Therapeutics acquisition for CAR-T R&D.
Risks
CH revenue flat (+1.2%) on slower category offtake and East/South regional impact. OTC growth muted in Q2.
Last quarter's promises, checked
Delivered
- EBITDA 25.5–26.5% → 27.1% (= BEAT)
- FY27 double-digit growth → H1 +15.1% (= BEAT, H1 only)
Partly delivered
- Acquisition debt repaid by FY28 → net debt ₹3,377→₹2,639 Cr (= PARTIAL, on track)
- Chronic share 50% medium-term → 37.4% (Q1 cited 40%; basis unclear, = PARTIAL)
Missed
- CH high-single to double-digit (Q2+) → +1.2% (= MISS)
- Capex 6–7% of revenue → H1 4.9% (= MISS, underspent)
Investor Presentation filed with BSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,490.00
- Market cap
- ₹1,02,848 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 45.9×Sector 46.5×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹716.1 Cr · +37.7% YoY
Mankind Pharma Other Announcement
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Mankind Pharma Debt & Borrowing: ₹1,400 Cr
Mankind Pharma has successfully completed the interest payment and full redemption of its Non-Convertible Debentures due on October 16, 2026.
- Value
- ₹1,400 Cr